Treatments for hepatitis B

Clinical Infectious Diseases

Volumn 39, Issue 9, 2004, Pages 1353-1362

  Asmuth, David M ^a   Nguyen, Hien H ^a   Melcher, Gregory P ^a   Cohen, Stuart H ^a   Pollard, Richard B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; UNCLASSIFIED DRUG; VALTORCITABINE; VIRUS PROTEIN;

ABDOMINAL PAIN; ASTHENIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG POTENCY; FEVER; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEADACHE; HEPATITIS B; HUMAN; MALAISE; MENTAL DISEASE; MOOD DISORDER; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SEIZURE; SOMNOLENCE; THROMBOCYTOPENIA; THYROID DISEASE;

ANTIVIRAL AGENTS; DRUG APPROVAL; HEPATITIS B, CHRONIC; HUMANS;

EID: 7644242419     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/425010     Document Type: Review

References (125)

1. Hepatitis B. Fact sheet World Health Organization (WHO)/204. Geneva: WHO, October 2000. Available at: http://www.who.int/ mediacentre/factsheets/fs204/ en. Accessed 5 October 2004.
2. Perz JF. Global burden of disease related to HBV and HCV infection [abstract 001]. HEP DART Conference (Kauai, Hawaii, 14-18 December 2003). Antiviral Res 2003:3.
3. Summary of notifiable diseases - United States 2001. MMWR 2003;50:1-136. Available at: http://www.cdc.gov/mmwr/PDF/wk/mm5053.pdf. Accessed 5 October 2004.
4. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
5. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-4.
6. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
7. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-7.
8. Rodriguez-Frias F, Buti M, Jardi R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995;22:1641-7.
9. Grandjacques C, Pradat P, Stuyver L, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000;33:430-9.
10. Orito E, Mizokami M, Sakugawa H, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001;33:218-23.
11. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology 2002;35:1274-6.
12. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-15.
13. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
14. Civitico GM, Locarnini SA. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994;203:81-9.
15. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-7.
16. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-22.
17. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-402.
18. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-40.
19. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol 2000;15:825-41.
20. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
21. Isaacs A, Lindenmann J. Virus interference: I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
22. Nokta MA, Reichman RC, Pollard RB. Pathogenesis of viral infections. In: Galasso GJ, Whitley RJ, Merigan TC, eds. Antiviral agents and viral diseases of man. 3rd ed. New York: Raven Press, 1990:49-85.
23. Baron S, Blalock JE, Dianzani F, et al. Immune Interferon: some properties and functions. Ann N Y Acad Sci 1980;350:130-44.
24. Taniguchi T, Takaoka A. The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14:111-6.
25. Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin Immunol 1998;10:383-90.
26. Heron I, Berg K, Cantell K. Regulatory effect of interferon on T cells in vitro. J Immunol 1976;117:1370-3.
27. Heron I, Hokland M, Hokland P, Berg K. Effects of interferon on human lymphoid cells and their function. Ann N Y Acad Sci 1980;350:112-20.
28. Isono E, Yamauchi K, Haruta I, Kamogawa Y, Hayashi N. Effect of alpha-interferon on hepatitis B virus-specific cytotoxic T cells. J Gastroenterol Hepatol 1995;10:24-9.
29. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-22.
30. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
31. Craxi A, DiBona D, Camma C. Interferon-α for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39:599-105.
32. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002;4:27-35.
33. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
34. Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-9.
35. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990;11(Suppl 1):S133-6.
36. Pasture G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992;14:221-5.
37. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
38. Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997;26:1621-5.
39. Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999;30:238-43.
40. Fried MW, Shiftman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
41. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
42. Craxi A, Cooksley WG. Pegylated interferons for chronic hepatitis B. Antiviral Res 2003;60:87-9.
43. Rosmorduc O, Sirma H, Soussan P, et al. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 1999;80:1253-62.
44. Abel K, Alegria-Hartman MJ, Rothaeusler K, Marthas M, Miller CJ. The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-α/β) and IFN-α/β- inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection. J Virol 2002;76:8433-45.
45. Ferez V, Tanno H, Villamil F, Fay O. Recombinant Interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol 1990;11(Suppl 1):S113-7.
46. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
47. Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
48. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
49. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
50. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
51. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80.
52. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
53. Tassopoulos NC, Volpes R, Pasture G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-96.
54. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
55. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
56. Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001;8:270-5.
57. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. J Med Virol 2002;66:435-51.
58. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
59. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38(Suppl 1):S90-103.
60. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
61. Zollner B, Petersen J, Schafer P, et al. Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 2002;34:1273-7.
62. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39:S111-5.
63. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
64. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5.
65. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-63.
66. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997;64:1624-7.
67. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis 2003;23:69-80.
68. Calio R, Villani N, Balestra E, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994;23:77-89.
69. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
70. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
71. Westland CE, Yang H, Delaney WE 4th, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.
72. Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-73.
73. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7.
74. Perrillo RP, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
75. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
76. Perrillo RP, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
77. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase 111 studies of adefovir dipivoxill. Gastroenterology 2003;125:107-16.
78. Delaney W 4th, Bartholomeusz A, Locarnini SA. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin Investig Drugs 2002;11:169-87.
79. Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003;38:545-53.
80. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 2002;9:393-9.
81. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3.
82. Raney AK, Hamatake RK, Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2003;12:1281-95.
83. Schalm S, De Man R, Janssen H. Combination and newer therapies for chronic hepatitis B. J Gastroenterol Hepatol 2002;17(Suppl 3): S338-41.
84. Yuen MF, Lai CL. Current and future antiviral agents for chronic hepatitis B. J Antimicrob Chemother 2003;51:481-5.
85. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992;36:2686-92.
86. Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993;37:441-7.
87. Schinazi RF, Gosselin G, Faraj A, et al. Pure nucleoside enantiomers of beta-2́,3́-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother 1994;38:2172-4.
88. Gish RG, Leung NW, Wright TL, et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002;46:1734-40.
89. Mommeja MH, Leung NW, Gish R. Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B [poster 239]. In: Program and abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology 2002:426
90. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002;36:710-22.
91. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8.
92. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8.
93. Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209-17.
94. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3.
95. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
96. Lai CL, Leung NW, Teo EK, et al. Results of a one-year international phase lib comparative trial of telbivudine, lamivudine, and the combination in patients with chronic hepatitis B [abstract J06]. In: Program and abstracts of the 54th Annual Meeting of the American Association for the Study of Liver Diseases (Boston). Alexandria, VA: American Association for the Study of Liver Diseases, 2003.
97. Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of β-L-thymidine and β-L-2́-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother 2002;46:1728-33.
98. Seifer M, Patty A, Faraj A, et al. In vitro studies on the mechanism of action of L-nucleoside inhibitors of hepatitis B virus replication reveal differences between LdT and lamivudine [abstract 80]. (Frontiers in Drug Development for Viral Hepatitis, 16-20 December 2001, Maui, HI). Antiviral Res 2001:82.
99. Zhou XJ, Lim SG, Lai CL, Pow DM, Brown N, Myers M. Pharmacokinetics of β-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection [abstract 100]. (Presented at: Frontiers in Drug Development for Viral Hepatitis, 16-20 December 2001, Maui). Antiviral Res 2001:92.
100. Lim SG, Young DY, Yuen M, et al. Safety and antiviral effects of val-LdC and LdT in patients with chronic hepatitis. B [Asian Pacific Association for the Study of the Liver 2002, 26-29 September, Taipei, Taiwan]. J Gastroenterol Hepatol 2002;17(Suppl 2):A26.
101. Zhou XJ. Dose optimization for LdT and other hepatitis B antivirals: importance of second-phase clearance and viral dynamics modeling [abstract H-464]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:287.
102. Standring DN, Bridges EG, Placidi L, et al. Antiviral Beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12(Suppl 1):119-29.
103. Bryant ML, Bridges EG, Placidi L, et al. Anti-HBV specific beta-L-2′-deoxynucleosides. Nucleosides Nucleotides Nucleic Acids 2001;20:597-607.
104. Safadi R, Israeli E, Papo O et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 2003;98:2505-15.
105. Rollier C, Sunyach C, Barraud L, et al. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 1999;116:658-65.
106. Lok AS, McMahon BJ. Chronic hepatitis B-AASLD practice guidelines. Hepatology 2001;34:1225-41.
107. Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol 2003;13:255-72.
108. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403-8.
109. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80.
110. Bertoletti A, Maini M, Williams R. Role of hepatitis B virus specific cytotoxic T cells in liver damage and viral control. Antiviral Research 2003;60:61-6.
111. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003;60:75-8.
112. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-26.
113. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-22.
114. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
115. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.
116. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
117. Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-10.
118. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002;36:799-804.
119. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
120. Barbara G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B: an Italian multicenter, randomized trial. J Hepatol 2001;35:406-11.
121. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
122. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
123. Perrillo RP, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
124. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
125. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998;27:294-7.